A new treatment for lung scarring due to Covid-19 infection

RT1840 is a repurposed, safe compound, formulated as an inhaled product to directly administer to the lung to prevent/reverse scarring (fibrosis)

Shareable draft

Check out A new treatment for lung scarring due to Covid-19 infection on @MedStartr Today RT1840 is a repurposed, safe compound, formulated as an inhaled product to directly administer to the lung to prevent/reverse scarring (fibrosis). #MedMo #MedStartrVentures

https://www.medstartr.ai/s/PnCC-_3J1jw

Get Involved in A new treatment for lung scarring due to Covid-19 infection

How We Help

Company Info

Clinical & IP

🔬

Clinical Validation

<ul> <li>RT175, the key API in our treatment, was originally developed as an oral medication for the treatment of neural degenerative diseases, beginning in 2002</li> <li>Human clinical experience: <ul> <li>611 people exposed to doses ranging from 100mg to 6g <ul> <li>Safe and well-tolerated</li> </ul> </li> <li>4 Phase 1 safety and PK studies</li> <li>4 Phase 2 Studies in Parkinson Disease and post-prostatectomy ED</li> <li>Longest and highest exposure was 4g/day for 2 years <em>po</em></li> </ul> </li> <li>Over $138MM spent on development to date</li> <li>Full IND-enabling safety, toxicology and  and PK/PD packages</li> <li>Based on unexpected and results in animal studies, the drug was repurposed to a low-dose aerosol to treat pulmonary fibrosis <ul> <li>New formulation</li> <li>IP well protected</li> </ul> </li> </ul> <p> </p>

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of A new treatment for lung scarring due to Covid-19 infection?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.

Get Involved in A new treatment for lung scarring due to Covid-19 infection